Tango Therapeutics

TNGXNASDAQ

Targets synthetic lethal interactions in genetically defined cancers, using a proprietary discovery platform to identify vulnerabilities in tumor cells with specific mutations.

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-09-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-09-09 · archived: kept for reference, not maintained · where each field comes from

OncologyPrecision Medicine

Key figures from SEC filings

TNGX filings on EDGAR →

Cash & investments

—

withheld: the parsed total disagreed with the balance sheet

Quarterly operating burn

$41.6M

average per quarter, Jan–Jun 2026

Cash runway

—

needs both cash and burn

Shares outstanding

168.6M

cover page of the latest filing

Read from TNGX's XBRL financial data; latest filing August 11, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Pre-revenue.

Upcoming catalysts

No upcoming catalyst for Tango Therapeutics has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.

Pipeline

Drug	Indication	Phase	Expected data
TNG462	MTAP-deleted solid tumors	Phase 1	Not disclosed	▼
TNG260	STK11-mutated solid tumors	Phase 1	Not disclosed	▼
TNG456	MTAP-deleted solid tumors including NSCLC and glioma	Phase 1	2026	▼
TNG908	MTAP-deleted solid tumors	Phase 1	Terminated	▼
TNG348	BRCA1/2 mutant or HRD+ solid tumors	Phase 1	Terminated	▼

What does Tango Therapeutics do?

Tango Therapeutics is a biotech company that develops cancer drugs for patients with specific genetic mutations. They focus on a concept called synthetic lethality, where they exploit weaknesses in cancer cells that have lost certain genes. Their main drug, TNG462, targets a protein called PRMT5, which becomes essential for cancer cells that have a deletion of the MTAP gene. This deletion occurs in about 10-15% of all cancers, making it a large market. Tango is also developing drugs for other genetic mutations, like STK11 and BRCA. They are in early-stage trials, so there is a lot of risk, but also potential for big rewards if the drugs work. Investors should watch for data readouts in the coming years, which could cause the stock to move significantly.

What to watch

Enrollment updates and early efficacy data from TNG462 trials

Any safety signals or dose-limiting toxicities in ongoing trials

Competitive data from Amgen's AMG 193 and Mirati's MRTX1719

Management commentary on pipeline prioritization and cash runway

Presentations at major oncology conferences like ASCO and ESMO

Investment thesis

High Risk

Bull case

Tango has a differentiated approach targeting synthetic lethality, with multiple shots on goal. Lead asset TNG462 shows promising early efficacy in MTAP-deleted tumors, a large patient population. The company has a strong cash position to fund operations into 2027. Upcoming data readouts in 2025-2026 could be transformative. Management has deep oncology expertise.

Bear case

Tango has had two pipeline discontinuations (TNG908 and TNG348), raising concerns about execution. The PRMT5 space is becoming crowded, with larger players like Amgen and Mirati. Early-stage data may not translate to registrational trials. The company is pre-revenue and will need to raise capital, potentially diluting shareholders. Competition from checkpoint inhibitors and other targeted therapies could limit market share.

Risk factors

⚠

Clinical trial failures or delays in enrollment

⚠

Competitive pressure from other PRMT5 inhibitors

⚠

Dependence on successful execution of multiple early-stage programs

⚠

Need for additional capital to fund operations beyond 2027

⚠

Potential safety issues with novel mechanisms

Trade TNGX commission-free on Webullvia Webull · Affiliate

Comparable companies

AMGN MRTXKURA

Sponsor's late-stage trial record

Tango Therapeutics has 6 Phase 2 or 3 studies on ClinicalTrials.gov: 2 stopped early, 4 ongoing.

Completed

Stopped early

Ongoing

Stopped early

NCT06065059Phase 1/2 · started 2023 · terminated
TNG348 in breast cancer · n=7
Reason given: Terminated due to safety
NCT05275478Phase 1/2 · started 2022 · terminated
TNG908 in locally advanced solid tumor · n=110
Reason given: Sponsor Decision - Business Decisions

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.